Increased emphasis on routine screening of chemicals for potential neurotoxicity has resulted in the development of testing guidelines and standardized procedures. A multiphased, tiered-testing strategy has been proposed by numerous expert panels to evaluate large numbers of chemicals. In a regulatory context, however, a formal tiered-testing approach is not used, mostly because of the constraints of differing regulatory authorities and the potential cost of such a testing strategy. Instead, current regulatory decision making utilizes all available animal and human data to identify a critical adverse effect which is then used for setting standards. Although the current decisionmaking process does not use a formal tiered-testing approach, it appears to identify chemicals with neurotoxic effects. An analysis of U.S. Environmental Protection Agency integrated risk information system (IRIS) indicates that about 20% of the chemicals having standards or health advisories are based on neurotoxicity. Environ Health Perspect 1 04(Suppl 2): 401-405 (1996) 
Introduction
There are between 50,000 and 100,000 chemicals used commercially and 1,000 to 1,600 new chemicals are submitted for premanufacture notification each year in the United States alone (1) . Several regulatory agencies in the United States are charged with enforcing legislation designed to protect the public and environment from the hazards of chemical exposure (2) . Premarket testing, for example, is required for pesticides by the U.S. Environmental Protection Agency (U.S. EPA) under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) and for drugs and food additives by the Food and Drug Administration (FDA). The Consumer Product Safety Commission (CPSC) and U.S. EPA can require testing of consumer products and industrial chemicals if there is a demonstrated justification for testing. The U.S. EPA can also require evaluation of industrial chemicals under the Toxic Substances Control Act (TSCA).
It is now recognized that many chemicals can have an adverse effect on the function and/or structure of the nervous system. Anger and Johnson (3), for example, identified more than 750 industrial chemicals as having neurotoxic effects following acute or repeated exposure. From the list of 750 chemicals, Anger (4) found 65 chemicals for which it has been estimated that 1 million or more people are potentially exposed. Of 588 chemicals listed by the American Conference of Government and Industrial Hygienists, 167 have threshold limit values based, in part, on neurologic or behavioral end points (5) .
Neurotoxic disorders, hearing loss, and psychological dysfunction are among the 10 leading occupational problems in the workplace (6) . A recent publication from the Office of Technology Assessment estimated that 3 to 28% of all chemicals may be neurotoxic (7) .
To Evans and Weiss (13) also indicated a third tier of testing involving assessment of human susceptibility to environmentally relevant chemicals using procedures studied in animals. Fine motor disturbances produced by exposure to methylmercury, for example, could be studied in humans using essentially the same methodology used in laboratory animals.
In a recent report published by the National Research Council (15), tiered testing was also discussed as a strategy for the assessment of chemicals. The tiered testing approach is similar to that described by Evans and Weiss (13) for the first two tiers. The NRC (15) report, however, indicated that mechanistic studies focusing on how a chemical produced a neurotoxic effect would be conducted at the third tier (Table 2) . In this case, a detailed examination would be undertaken of a chemical's effect at several levels of nervous system organization (i.e., behavioral, cellular, molecular). Information derived from these studies might be used in the development of biologically based dose-response models. The approach taken by Choi (16) linking the neurotoxicity produced by an excitatory amino acid-mediated increase in intracellular calcium is an example of a mechanistic study.
In a recent overview of screening approaches, Tilson Although a formal tier-testing strategy is not routinely employed in regulatory decision making, it is clear regulatory decisions are based on data obtained from procedures normally defined as being first-or second-tier tests. For example, for some chemicals regulated under TSCA, the only available information is the structure and some estimation of the levels and numbers of people that might be exposed (21) . A decision to require testing might be based on structure-activity relationships, production levels, and proposed use. Tier-one tests such as an FOB, motor activity, and neuropathology might be used to provide the data in such cases. On the other hand, if there are data that suggest neurotoxicity or if the chemical is already on the market and neurotoxicity has been reported in occupational or environmental settings, then testing might be required; depending on the circumstances, first-and/or secondtier tests might be used to characterize the nature of the neurotoxicity.
The use of data from first-or secondtier testing in a decision-making context is dependent on the process by which regulatory risk assessments are performed. At the U.S. EPA, quantitative risk assessment begins with the definition of a critical adverse effect based on evaluation of all the available human and animal data ( Figure  2) . Determination of an adverse critical effect is based on data obtained from animal experiments using first-and/or secondtier tests, mechanistic studies, or from human epidemiological, clinical, or case studies, from which a critical study is identified. The critical effect from that study along with supporting data are then used to determine a lowest observed adverse effect level (LOAEL) or no observed adverse effect level (NOAEL) to calculate a reference dose (RfD) for regulatory decision making. The RfD is an estimate of a daily exposure to the human population that is likely to be without appreciable risk over a lifetime (22) Figure 2 . Data from all tiers of animal testing and all human data from epidemiology, case studies, or clinical observations and experimental studies are evaluated and a critical adverse effect is determined to calculate standards for regulatory action.
sensitivity, animal-to-human extrapolation, less-than-lifetime exposures, and use of a LOAEL rather than a NOAEL. An additional uncertainty factor for an incomplete dataset has also been used. A modifying factor ranging from 1 to 10 may also be used in the denominator to reflect any uncertainties in the critical study used to establish the critical effect (22, 23) . It is unlikely that the data used to determine the critical adverse effect would be derived from a formal systematic tiertesting strategy. From an industry or pesticide registrant's point of view, the outcome of further testing along with the added time and expense may create disincentives for tiered testing. Consider the hypothetical example in Figure 3 . The results of first-tier screening studies suggest a chemical has neurotoxic potential. ask about the capability of the current system to detect and set standards for chemicals having neurotoxic effects. To determine this, the integrated risk information system (IRIS) of the U.S. EPA was accessed, and the use of neurotoxicological findings in establishing standards and health advisories (HAs) was determined. IRIS is a computerized database designed by the U.S. EPA's Office of Health and Environmental Assessment for use by staff at U.S. EPA reported by the OTA (7) that 3 to 28% of all chemicals in the environment may be neurotoxic. The chemicals identified in the IRIS database included a number of solvents (e.g., styrene, toluene, xylenes, acrylamide, n-hexane, propylene glycol monomethyl ether), pesticides (e.g., carbofuran, methyl parathion, pydrin, thiram, methamidophos), and metals (e.g., manganese, methylmercury).
Therefore, in spite of the lack of a tiered-testing strategy, neurotoxic effects are used by the U.S. EPA as the basis for setting standards and health advisories.
Summary and Conclusions
A tier-testing strategy for the assessment of neurotoxicity has been proposed by numerous expert panels and, most recently, by the NRC (15) . Although such a testing strategy is conceptually attractive, it is not practical in most regulatory contexts. The current decision-making process at U.S. EPA utilizes all available animal data collected in hazard identification, characterization, or mechanism-of-action studies, as well as human epidemiological, case, and clinical studies, to arrive at a critical adverse effect. The risk assessment process then utilizes the critical adverse effect to support regulatory decision making. Considering the proportion of cases in which neurotoxicity is used as the critical adverse effect, the current risk assessment system identifies about 20% of the chemicals listed as neurotoxic, which agrees well with the range of values suggested by the OTA (7). As more is learned about the mechanism of action of neurotoxic chemicals, future testing may evolve into a modified tier-testing strategy where short-term, in vitro tests are used at the first tier and information from these studies is used to determine if testing at the second tier should occur. Second-tier tests would indude in vivo tests selected on the basis of the results of the first tier.
